TY - JOUR
T1 - The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy
AU - Caimi, Paolo F.
AU - Ardeshna, Kirit M.
AU - Reid, Erin
AU - Ai, Weiyun
AU - Lunning, Matthew
AU - Zain, Jasmine
AU - Solh, Melhem
AU - Kahl, Brad S.
AU - Hamadani, Mehdi
N1 - Funding Information:
PFC reports research funding from ADC Therapeutics; grants Genentech. Consulting: ADC Therapeutics, Kite Pharmaceuticals, Verastem, Seattle Genetics, Amgen TG Therapeutics. Speaker's bureau: Celgene KMA reports research funding from ADC Therapeutics. Consulting from ADC Therapeutics, Celgene, Gilead, Takeda, Roche and Beigene. Support by the University College London (UCL)/UCL Hospitals (UCLH) Biomedical Research Unit. ER reports research funding from ADC Therapeutics. WA reports research support Nurix Therapeutics. Consulting: ADC Therapeutics, Nurix, Kymera. ML reports research funding from ADC Therapeutics, BMS, Curis. Consulting: Kite, Janssen, Karyopharm, Astra-Zeneca, Acrotech, BeiGene, Legend, ADC Therapeutics, Spectrum, Morphosys, Daiichi Sankyo, Myeloid Therapeutics, Kyowa Kirin. JMZ reports research funding from ADC Therapeutics. Consulting: Seattle Genetics, Kyowa Kirin, Verastem, Secura Bio, Legend Biotech, Ono Therapeutics. MS reports research funding from ADC Therapeutics, Partner therapeutics. Advisory Amgen, Seattle genetics. Speaker's Bureau: Amgen, Celgene. BSK reports research funding from ADC Therapeutics. Consulting: ADC Therapeutics. MH reports Research Support/Funding: Takeda Pharmaceutical Company; Astellas Pharma. Consulting/advisory board: Incyte Corporation; ADC Therapeutics; Celgene Corporation; Pharmacyclics, Magenta Therapeutics, Omeros, AbGenomics, Verastem, TeneoBio. Speaker's Bureau: Sanofi Genzyme, AstraZeneca, BeiGene.
Funding Information:
Additional support in data retrieval and analysis, as well as manuscript accuracy review by ADC Therapeutics Personnel, including Paul Thaler, Wendy Ma, and Yajuan Qin.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/5
Y1 - 2022/5
N2 - Introduction: Chimeric antigen receptor T (CAR-T) cells targeting CD19 result in durable responses in approximately 40% of DLBCL patients. Loncastuximab tesirine, an antibody drug conjugate targeting CD19 with a pyrrolobenzodiazepine payload, has activity against DLBCL. Patients and Methods: We evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial. Results: Six patients (46%) had responses to loncastuximab (CR, n = 2). Median OS, PFS and duration of response after loncastuximab were 8.2, 1.4 and 8 months, respectively. Conclusion: Loncastuximab can achieve responses in patients progressing after CAR-T cells. Sequencing CD19-targeting therapies is possible in cases without CD19 loss.
AB - Introduction: Chimeric antigen receptor T (CAR-T) cells targeting CD19 result in durable responses in approximately 40% of DLBCL patients. Loncastuximab tesirine, an antibody drug conjugate targeting CD19 with a pyrrolobenzodiazepine payload, has activity against DLBCL. Patients and Methods: We evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial. Results: Six patients (46%) had responses to loncastuximab (CR, n = 2). Median OS, PFS and duration of response after loncastuximab were 8.2, 1.4 and 8 months, respectively. Conclusion: Loncastuximab can achieve responses in patients progressing after CAR-T cells. Sequencing CD19-targeting therapies is possible in cases without CD19 loss.
KW - CAR-T cell failures
KW - Diffuse large B cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85122947297&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2021.11.005
DO - 10.1016/j.clml.2021.11.005
M3 - Article
C2 - 35034868
AN - SCOPUS:85122947297
SN - 2152-2650
VL - 22
SP - e335-e339
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 5
ER -